Gynecologic Cancer

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance with or without Bevacizumab versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy

Study Purpose: To test the safety of sac-TMT when given alone or with bevacizumab; to see how well sac-TMT +/- bevacizumab works compared to standard of care treatment; and to compare the quality of life of participants receiving the study treatment vs. standard of care treatment

Status: Recruiting

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as First-line Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Study Purpose: To test the safety and efficacy of sacituzumab tirumotecan (sac-TMT) in people with cervical cancer that has returned or spread to other parts of the body during or after receiving treatment, or is not likely to be cured with surgery and/or radiation

Status: Recruiting

Official Title: A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)

Study Purpose: To understand how well INCB123667 works, how safe it is, and how well it is tolerated in people with platinum-resistant ovarian cancer whose tumors have high levels of cyclin E1.

Status: Recruiting

Official Title: A Randomized, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Study Purpose: To find out about the safety and efficacy (how well a drug works) of AZD5335 for the treatment of platinum-resistant ovarian cancer by comparing AZD5335 to standard of care therapies.

Status: Recruiting

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Study Purpose: To test the safety, efficacy, and effect on quality of life of sac-TMT when given alone, with bevacizumab, or compared to no maintenance treatment.

Status: Recruiting

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research

Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.

Status: Recruiting

Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Study Purpose: The purpose of the study is to compare two surgical procedures and their ability to decrease the risk of developing ovarian cancer for pre-menopausal women with BRCA1 mutations.

Status: Recruiting

Official Title: Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment Trial  

Study Purpose: To investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer patients with a macrometastasis and/or extracapsular extension in the SN.

Status: Recruiting

Official Title: Testing the addition of Herceptin Hylecta or Phesgo to the usual chemotherapy for HER2 positive endometrial serous carcinoma or carcinosarcoma.

Study Purpose: To determine if the addition of the study drugs will lower the chance of this disease from coming back.

Status: Recruiting

Official Title: A Randomized Phase III Trial of Carboplatin, Paclitaxel, and Pembrolizumab versus Carboplatin, Paclitaxel, and Bevacizumab versus Carboplatin, Paclitaxel, Pembrolizumab and Bevacizumab in the Treatment of PMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

Study Purpose: To find out if adding a drug that blocks cancer blood vessel growth (bevacizumab) to the usual approach of paclitaxel and carboplatin with or without pembrolizumab immunotherapy lowers the chance of endometrial cancer growing or spreading.

Status: Recruiting